Lomitapide, as an MTP inhibitor, has clear contraindications for patients with moderate to severe liver disease, pregnant women, and lactating women. Strict adherence to medication contraindications is necessary to ensure patient safety. The following provides a detailed explanation of the medication risks and precautions for different taboo groups.

1 patient with moderate to severe liver disease

Lometapine is contraindicated for patients with moderate to severe liver dysfunction (total bilirubin>1.5 times the upper limit of normal). Drugs are mainly metabolized through the liver, and liver dysfunction may lead to drug accumulation, exacerbating the risk of liver injury. Patients with mild liver damage also need to closely monitor their transaminase levels.

2 Pregnant women

Pregnant women are absolutely prohibited from using Lometapai. Animal studies have shown that drugs have embryonic toxicity and may lead to abnormal fetal development. Women of childbearing age should confirm that they are not pregnant before taking medication, and take effective contraceptive measures during treatment and after discontinuing medication.

3 lactating women

It is not clear whether the drug is secreted through breast milk, but there is a potential infant risk. It is recommended to stop breastfeeding during the treatment period and at least 2 weeks after the last dose. If medication is necessary, a breast milk replacement plan should be prepared in advance.

4 Other high-risk groups

The safety of pediatric patients has not been established, and elderly patients need to be carefully evaluated for liver and kidney function. Although severe renal insufficiency is not an absolute contraindication, there is a lack of relevant research data, and it is recommended to avoid use or closely monitor.

5 Key points for managing taboo groups

All contraindicated individuals must undergo a thorough risk assessment before taking medication. Patients with moderate to severe liver disease need alternative treatment plans, pregnant women need to consult with contraception in advance, and lactating women need to develop feeding plans. Any suspected contraindications should be immediately discontinued and medical attention sought.